Maggie L. Shaw

The behavioral economic biases of 43 African American young adults aged 18 to 24 were evaluated on 4 fronts: present bias, information salience, overoptimism, and loss aversion.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.

Dupilumab treatment delivered at a specialized tertiary care center has great potential to improve patient clinical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP).

Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

Study investigators stress the importance of health care professionals familiarizing themselves with risk factors among a more diverse patient population.

This subanalysis of data from the VIRGO study encompassed 2979 patients who had an acute myocardial infarction (AMI), or heart attack, between ages 18 and 55 years; outcomes evaluated included all-cause and cause-specific acute events requiring hospitalization in the year after discharge for a heart attack.

It is likely that social determinants of health (SDOH) may affect the differences in outcomes from multiple sclerosis (MS) that we see among Black/African American and Hispanic/Latinx populations, absent more data on their genetics and ancestry, noted Mitzi Joi Williams, MD, FAAN.

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

The potential ethical implications for goals of care discussions between surrogate decision makers and health care providers concerning patients who reside in a state of cognitive motor dissociation were investigated in this new study from a team at Columbia University and New York Presbyterian Hospital.

Much more work needs to be done surrounding multiple sclerosis (MS) and treating pregnant patients safely, noted Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic.

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.

Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

There are limited data on potential disparities in dementia medication use in the outpatient setting, with study authors highlighting that the benefits of these medications are not equitably distributed along racial and ethnic lines because of usage differences.

A study from investigators in the Quantitative Health Science, Neurology, and Radiology departments of Mayo Clinic investigated if and how social and structural determinants of health (SSDOH) might influence mild cognitive impairment and/or risk of dementia among participants of the Mayo Clinic Study of Aging.

Terminology and concepts relevant to the care of transgender and gender-diverse individuals and best practices for optimizing neurologic care in this patient population were covered in the session “Neurologic Conditions in Transgender Patients” on Sunday, April 23, at the American Academy of Neurology annual meeting.

A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.

The investigators of this study wanted to know if hospitals that cared for a high proportion of Black patients delivered care for heart failure (HF) that differed in quality from that provided by other hospitals.

In several abstracts presented at this year's American Academy of Neurology Annual Meeting, Mitzi Joi Williams, MD, FAAN, Joi Life Wellness Neurology Clinic, explores multiple sclerosis–related outcomes in diverse patient populations.

Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.

For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.

The annual meeting of the American Academy of Neurology (AAN) will take place April 22-27 in Boston, presenting in a hybrid format a schedule packed with continuing medical education sessions, poster presentations, and cutting-edge science.

Using data from the PROVE-HF study, investigators conducted a subanalysis of outcomes among patients receiving sacubitril/valsartan who did and did not have ischemic heart disease.

Investigators compared outcomes for severe mental illness between patients with both chronic skin conditions and healthy controls, using data from the UK Clinical Practice Research Datalink GOLD.

At present, there are no approved therapies for pre–heart failure with preserved ejection fraction (pre-HFpEF); instead, cardiovascular risk factor management is often utilized in this patient population.

Health status and health-related quality of life (QOL) outcomes were compared between patients with severe cases of chronic rhinosinusitis with nasal polyps (CRSwNP) and a general patient population.

There are higher risks of several major adverse cardiovascular events (MACEs) following intracerebral hemorrhage (ICH), and they include recurrent ICH, ischemic stroke, and myocardial infarction.

Sashi Naidu, MD, is director of research at Carolina Blood and Cancer Care Associates, where the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients and prevent care fragmentation.

With the global market for biologics estimated at $382 billion just last year, and a projected global drug spend of close to $1.5 trillion by 2027, the landscape is ripe for biosimilars to help decrease the health care system’s cost burden.